ArticleCells2021
Osteosarcoma in Adolescents and Young Adults.
Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Deep learning applications in osteosarcoma MRI: A systematic review of recent advances in AI-based osteosarcoma diagnosis.PloS one · 2026Pooled it
- Systematic Review of joint preservation limb salvage in osteosarcoma around the knee.Frontiers in oncology · 2025Pooled it
- The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable.Cancers · 2026Review
- E3 Ubiquitin Ligase ITCH Enhances P53 Ubiquitination-Dependent Degradation and Drives Osteosarcoma Tumorigenesis.Molecular cancer research : MCR · 2026Article
- A strategy of 3D-printed Ta4C3 MXenes nanohydroxyapatite/methacryloylated silk fibroin scaffolds for postsurgical management of osteosarcoma.Journal of biological engineering · 2026Article
- Multi-Omics-Guided Discovery ofMarine drugs · 2026Article
- Article
- Single-Cell Transcriptomic Analysis of Chemotherapy-Induced Changes in Osteosarcoma With a Pyroptosis-Related Gene-Based Prognostic Model.Journal of cellular and molecular medicine · 2026Article
- An "off-on" CdTe QDs fluorescent nanosensor for detecting apoptosis in osteosarcoma and evaluating chemotherapy response.Scientific reports · 2026Article
- Correlation between systemic immune inflammatory index and prognostic nutritional index and prognosis of osteosarcoma patients and construction of prediction model.BMC musculoskeletal disorders · 2026Article
- Survival differences in pulmonary metastatic osteosarcoma between pediatric and adult institutions.Journal of pediatric surgery · 2026Article
- Celastrol Enhanced Doxorubicin-Mediated Apoptosis in Saos-2 Osteosarcoma Cells.BioMed research international · 2026Article
- Exploring Bone Oncology in a Medically Underserved Area: A Retrospective Cohort of Bone Metastases and Malignant Bone Neoplasia in the Rio Grande Valley.Southern medical journal · 2025Article
- Genomic Characterization of Papillary Thyroid Carcinoma: Age Differences in Tumor Aggressiveness and Immune Infiltration.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI.Journal of imaging informatics in medicine · 2025Article
- Identification of endothelial INSR as an osteosarcoma-related biomarker and therapeutic target based on weighted gene co-expression network analysis.Discover oncology · 2025Article
- Survival profiles and associated factors for overall and cancer specific survival in patients with chondroblast and fibroblastic osteosarcoma.Scientific reports · 2025Article
- The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The epidemiology of osteosarcoma in adolescents and young adults (AYA) remains unclear. We aimed to assess and compare the clinical features of osteosarcoma between AYA and other age groups. We retrieved osteosarcoma cases diagnosed between 1999 and 2017 from the Korea Central Cancer Registry. We compared survival trends and clinical characteristics between AYA and other age groups. AYA comprised 43.3% (1309/3022) of the osteosarcoma cases. Compared to other age groups, the male-to-female ratio was highest in AYA (1.61:1). The proportion of tumors located in an extremity was 80.3% in AYA, which was lower than in young children (92.5%) or pubertal children (93.8%) but higher than in adults (55.7%) or the elderly (47.5%). As for treatments, 71.2% of AYA received local treatment and systemic chemotherapy, and 28.8% received only local treatment (surgery: 261, radiotherapy: 9, surgery and radiotherapy: 5). The 5-year overall survival (OS) was lower in AYA (68%) than in young children (78%) or pubertal children (73%) but higher than in adults (47%) or the elderly (25%). When AYA were divided into five subgroups by age, patients aged 15-19 years constituted the largest proportion (45.4%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.